Clinical Trial - Obinutuzumab and Ibrutinib - Non-Hodgkin's Lymphomas

Sidney Kimmel Cancer Center at Thomas Jefferson University is running a clinical trial to test drugs called Ibrutinib and Obinutuzumab to treat Non-hodgkin’s Lymphoma. This phase II trial studies how well obinutuzumab and ibrutinib work as front line therapy in treating patients with indolent non-Hodgkin’s lymphoma. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab and ibrutinib may work better in treating patients with non-Hodgkin’s lymphomas.

The drugs are Ibrutinib and Obinutuzumab.

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II, Single Arm, Open Label Multi-center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent Non-Hodgkin’s Lymphomas
Actual Study Start Date : February 20, 2018
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : January 2022

For enrollment please visit

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.